Slide 1: Hui a Tau Annual Shareholders Meeting October 2022
Hui a Tau Annual Shareholders Meeting October 2022
Slide 2: East Cape New Zealand
East Cape New Zealand
Slide 3: Hui a Tau Annual Shareholders Meeting October 2022
Hui a Tau Annual Shareholders Meeting October 2022
Slide 4: Rua Bioscience disclaimer
Rua Bioscience Limited (Rua) is a New Zealand pharmaceutical company aiming to be a leading producer of cannabinoid derived medicines. This presentation and the information contained in or accompanying this presentation are not, and are under no circumstances to be construed as, an invitation to sub
Slide 5: How to Participate in Virtual/Hybrid Meetings (Q&A)
How to Participate in Virtual/Hybrid Meetings (Q&A) Shareholder & Proxyholder Q&A Participation Written Questions Questions may be submitted ahead of the meeting. If you have a question to submit during the live meeting, please select the Q&A tab on the right half of your screen at anytime. Type you
Slide 6: How to Participate in Virtual/Hybrid Meetings (Voting)
How to Participate in Virtual/Hybrid Meetings (Voting) Shareholder & Proxyholder Voting Once the voting has been opened, the resolutions and voting options will allow voting. To vote, simply click on the Vote tab, and select your voting direction from the options shown on the screen. You can vote fo
Slide 7: Board of Directors – Leadership to Grow Rua
Board of Directors – Leadership to Grow Rua TREVOR BURT PANAPA EHAU BRETT GAMBLE ANNA STOVE MARTIN SMITH Independent Director, Co-Founder Director Independent Director Independent Director Chairman Co-founder of a 20 years’ global 25 years’ experience 25 years’ experience Global executive roles numb
Slide 8: 8
8
Slide 9: Leadership Changes
Leadership Changes Rob Mitchell CEO Since his appointment as CEO in February 2020, Rob has built a world-class team, leading them through significant milestones. • Rua launched on the NZX • Gained GMP certification. • Launched our first product in New Zealand. • Developed new global market opportuni
Slide 10: Co-Founder Refocuses
Co-Founder Refocuses Manu Caddie Co-Founder, Kaihautu innovation and Regulation Cofounded Rua in 2016. Is part of a small group who can claim to have built the industry in Aotearoa from the ground up. Globally recognised leadership and expertise in the regulatory and research areas. Constant advocat
Slide 11: Agenda
1. Company Overview and Chair’s Address 2. Managing Director’s Presentation 3. Annual Results Presentation Agenda 4. Shareholder Questions 5. Ordinary Resolutions 1. Auditors Remuneration 2. Re-election of Trevor Burt 3. Re-election of Brett Gamble 4. Re-election of Teresa Ciprian 6. General Busines
Slide 12: Company Overview and Chair’s Address
Company Overview and Chair’s Address 12
Slide 13: Our Strategy – Focus and Objectives
Te Rautaki o Rua Our Strategy – Focus and Objectives Creating Unique Product and • Create unique, sustainable and protected IP, cultivation techniques Plant IP • Develop commercially viable varieties of cultivars • Use research partners to develop IP • Create new, protected product formulations Deve
Slide 14: Achievements at a Glance
Māwhiti mai ki ngā Whakatutukitanga Achievements at a Glance Rua received Rua received Rua welcomed Rua Rua launched Rua received Good verification the East Coast shareholders its first its narcotic Manufacturing that its first Cannabis approved the medicine for license through Practice (GMP) medici
Slide 15: Volatility in the NZ Market
Volatility in the NZ Market 40% 20% 0% -20% NZX 50 Rua Cannasouth -40% Greenfern Industries -60% -80% -100% Jul 21 Aug 21 Sep 21 Oct 21 Nov 21 Dec 21 Jan 22 Feb 22 Mar 22 Apr 22 May 22 Jun 22 Jul 22 Aug 22 Sep 22 15
Slide 16: Managing Director’s Presentation
Managing Director’s Presentation 16
Slide 17: FY22: An Overview
Tirohanga Whānui FY22: An Overview In past year, Rua has been focused on preparing for market entry Ø Securing partners and developing the frameworks and strategies that will give the company the best chance of success both at home and globally. 17
Slide 18: Rua’s Operational Priorities
Rua’s Operational Priorities Leveraging our Cann cultivation and processing facility to launch products to Germany Developing the European market Manufacturing CBD100 in Gisborne & increasing our market share in NZ Continue to discover interesting new, illicit varieties at Ruatorea - ultimately grow
Slide 19: Leveraging our Cann Production Capacity to Service Global Markets
Leveraging our Cann Production Capacity to Service Global Markets Cann Group have announced that the GMP manufacturing licence for the Company’s flagship Mildura facility, has been extended to cover the manufacture and release of finished dried flower products for patient use. Rua will leverage this
Slide 20: Rua Significantly Advances German Market Entry
Rua Significantly Advances German Market Entry We have just received our first order from German distributer, Nimbus Health, marking a significant commercial milestone and cementing export revenues. 20
Slide 21: Advancing our Export Strategy
Advancing our Export Strategy Going global to support local Germany Poland Czechia The United Kingdom Source: The European Cannabis Report: 7th edition: Reports. Prohibition Partners. (2022, April 8). Ret’d May 25, 2022. 21
Slide 22: Entering the NZ Market
Entering the NZ Market The launch of Rua’s first medicine in Aotearoa was a milestone for New Zealand patients, prescribers and the medicinal cannabis industry. 22
Slide 23: NZ market grows as practitioners increasingly willing to trial medicinal cannabis
NZ market grows as CBD PRODUCTS (units) practitioners are SUPPLIED PER ANNUM TO THE NZ MARKET increasingly willing to trial medicinal cannabis New Zealand’s CBD market is growing rapidly off a small base. Source: Ministry of Health, 2022 23
Slide 24: Ruatorea - our home of genetic innovation
Ruatorea - our home of genetic innovation Continue to discover interesting new, illicit varieties at Ruatorea - ultimately growing chosen varieties at scale in Australia. 24
Slide 25: Rua recently exported its first seeds to Australia
Rua recently exported its first seeds to Australia It is a first step in establishing the processes we need to send genetics to Australia where we can grow at a global scale. It also demonstrates that, in time, we will be able to export unique East Coast genetics from Ruatorea to the world. 25
Slide 26: We are a business with a deep sense of kaitiakitanga
We are a business with a deep sense of kaitiakitanga Impact Area Target FY22 Status Environmental Toitū Envirocare carbon audit completed and transition plan approved. In progress Sustainable packaging policy adopted and recyclable packaging investigated. Complete GACP certification process undertak
Slide 27: Baseline for CO2 emissions established
Baseline for CO2 emissions established, plan in progress to reduce 27
Slide 28: Continuing our commitment to drive community change
Continuing our commitment to drive community change Focusing on inspiring the next generation of scientists and entrepreneurs. 28
Slide 29: Leadership Changes
IR (ON Leadership Changes
Slide 30: Rightsizing Rua Rebuilding Culture and Kaupapa
Rightsizing Rua Rebuilding Culture and Kaupapa 30
Slide 31: Pathway to Sustainable Revenue
Pathway to Sustainable Revenue Q1 Q2 Q3 Q4 Q4 2022 2022 2022 2022 2022 First New First First Zalm Acquisition Domestic Revenue Global Markets Genetic Export German Export Securing long- Product available Expanded Further advances Export sales term supply in New Zealand as strategy Rua’s IP and immin
Slide 32: Annual Results
Annual Results 32
Slide 33: Rua Receives First Revenues
Rua Receives First Revenues Nga Pūtea Financial Highlights Total income $646k Profit & Loss Investment in R&D $2.98m Rua’s annual financial results for the year the ended 30 June 2022. Loss before tax $7.49m 33
Slide 34: Rua Remains Well Capitalised
Rua Remains Well Capitalised Nga Pūtea Financial Highlights Cash, Cash Equivalents & Investments $9.94m Balance Sheet Total Assets $33.57m Rua’s annual financial results for the year the ended 30 June 2022. Total Liabilities $9.38m Net Assets $24.2m 34
Slide 35: Investing in the Future
Investing in the Future Nga Pūtea Financial Highlights Net cash outflow from operating activities $6.84m Cashflow Net cash inflow from investing activities $5.59m Rua’s annual financial results for the year the ended 30 June 2022. Net cash outflow from financing activities $209k 35
Slide 36: Shareholder Questions
Shareholder Questions 36
Slide 37: Ordinary Resolutions
Ordiriary « _ -Resolutianigs abv = : xt
Slide 38: Resolution One
Resolution One That the Board be authorised to fix the auditor’s remuneration. 38
Slide 39: Resolution Two
Resolution Two That Trevor Burt be re-elected as a director of Rua. BSc, Chartered Fellow of the Institute of Directors. Trevor brings extensive corporate executive and governance experience to Rua Bioscience, having served in global executive roles with a Fortune 500 company, on the boards of innov
Slide 40: Resolution Three
Resolution Three That Brett Gamble be re-elected as a director of Rua. BCom, Chartered Accountant (member of CA ANZ). Brett is an investment and finance specialist with global connectivity having lived and worked in USA, UK, Australia, and New Zealand. He is currently CEO of Gough Investments and Ex
Slide 41: Resolution Four
Resolution Four That Teresa Ciprian be re-elected as a director of Rua. Chartered Member of the Institute of Directors. Teresa has an exceptional background in highly competitive global FMCG businesses. A Chartered member of the Institute of Directors, Teresa brings strong governance capability havi
Slide 42: General Business
General Business 42
Slide 43: Rua Bioscience
RUA BIOSCIENCE